Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MannKind (MNKD) Stock Price

Media coverage about MannKind (NASDAQ:MNKD) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.8210590750664 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern’s analysis:

How to Become a New Pot Stock Millionaire

NASDAQ MNKD traded up $0.19 on Thursday, hitting $2.38. 2,043,482 shares of the company were exchanged, compared to its average volume of 3,610,605. The company has a market cap of $269.39, a price-to-earnings ratio of -2.05 and a beta of 2.91. The company has a quick ratio of 0.62, a current ratio of 0.65 and a debt-to-equity ratio of -0.48. MannKind has a 1-year low of $0.67 and a 1-year high of $6.96.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $3.22 million. equities analysts expect that MannKind will post -0.85 earnings per share for the current year.

A number of brokerages recently issued reports on MNKD. BidaskClub raised shares of MannKind from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Zacks Investment Research upgraded shares of MannKind from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Thursday, March 29th. S&P Equity Research reduced their target price on shares of MannKind from $3.49 to $2.77 in a research note on Thursday, January 25th. Finally, Maxim Group restated a “hold” rating on shares of MannKind in a research note on Tuesday, January 30th. Five research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company’s stock. MannKind presently has an average rating of “Sell” and a consensus price target of $1.88.

ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is owned by of BBNS. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://baseballnewssource.com/2018/04/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-mannkind-mnkd-stock-price/2028519.html.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.